(Q45772317)

15 December 2017

title

Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine (English)

1 reference

15 December 2017

author name string

Peck R

1

1 reference

15 December 2017

Wiggs R

2

1 reference

15 December 2017

Callaghan J

3

1 reference

15 December 2017

Wootton R

4

1 reference

15 December 2017

Crome P

5

1 reference

15 December 2017

Fraser I

6

1 reference

15 December 2017

Frick L

7

1 reference

15 December 2017

Posner J

8

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 January 1996

1 reference

15 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

15 December 2017

volume

59

1 reference

15 December 2017

issue

1

1 reference

15 December 2017

page(s)

22-31

1 reference

15 December 2017

Pharmacokinetics and tolerability of single oral doses of 882C87, a potent, new anti-varicella-zoster virus agent, in healthy volunteers

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990020-X

The bioavailability and disposition of 1-(beta-D-arabinofuranosyl)-5-(1-propynyl)uracil (882C87), a potent, new anti-varicella zoster virus agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990020-X

Enhancing effect of bromovinyldeoxyuridine on antitumour activity of 5-fluorouracil in mice bearing MOPC-315 plasmacytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990020-X

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990020-X

Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990020-X

Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990020-X

Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil against adenocarcinoma 755 in mice. Increased therapeutic index and correlation with increased plasma 5-fluorouracil levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990020-X

5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990020-X

5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990020-X

Determination of 1-(beta-D-arabinofuranosyl)-5-(1-propynyl)-uracil and a metabolite, 5-propynyluracil, in plasma using ASTED (automated sequential trace enrichment of dialysates) combined, on-line, with high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990020-X

Automated sequential trace enrichment of dialysates combined with high-performance liquid chromatography and automated heart-cutting for the determination of the nucleoside 1-(beta-D-arabinofuranosyl)-5-(1-propynyl)uracil and its metabolite 5-propyn

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990020-X

Degradation of pyrimidines and pyrimidine analogs--pathways and mutual influences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990020-X

10.1016/S0009-9236(96)90020-X

7 January 2021

Identifiers

DOI

1 reference

15 December 2017

PubMed ID

8549030

1 reference

15 December 2017